{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:01:57Z","timestamp":1786978917979,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":48,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031920325","type":"print"},{"value":"9783031920332","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-92033-2_23","type":"book-chapter","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T17:44:14Z","timestamp":1751478254000},"page":"361-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Iron Chelation Therapy"],"prefix":"10.1007","author":[{"given":"Maria Domenica","family":"Cappellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Scaramellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"23","key":"23_CR1","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","volume":"22","author":"LJ Anderson","year":"2001","unstructured":"Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH et al (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22(23):2171\u20132179","journal-title":"Eur Heart J"},{"issue":"4","key":"23_CR2","first-page":"493","volume":"55","author":"K Balveer","year":"2000","unstructured":"Balveer K, Pyar K, Wonke B (2000) Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malaysia 55(4):493\u2013497","journal-title":"Med J Malaysia"},{"issue":"3","key":"23_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1586\/ehm.11.29","volume":"4","author":"C Borgna-Pignatti","year":"2011","unstructured":"Borgna-Pignatti C, Gamberini MR (2011) Complications of thalassemia major and their treatment. Expert Rev Hematol 4(3):353\u2013366","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"23_CR4","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2005-07-2933","volume":"107","author":"C Borgna-Pignatti","year":"2006","unstructured":"Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR et al (2006) Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 107(9):3733\u20133737","journal-title":"Blood"},{"issue":"2","key":"23_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1006\/abio.2001.5378","volume":"299","author":"W Breuer","year":"2001","unstructured":"Breuer W, Cabantchik ZI (2001) A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 299(2):194\u2013202","journal-title":"Anal Biochem"},{"issue":"1","key":"23_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ajh.2830420116","volume":"42","author":"GM Brittenham","year":"1993","unstructured":"Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW et al (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 42(1):81\u201385","journal-title":"Am J Hematol"},{"issue":"11","key":"23_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJM199009133231104","volume":"323","author":"N Bronspiegel-Weintrob","year":"1990","unstructured":"Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ (1990) Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med 323(11):713\u2013719","journal-title":"N Engl J Med"},{"issue":"24","key":"23_CR8","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMcibr1304338","volume":"368","author":"C Camaschella","year":"2013","unstructured":"Camaschella C (2013) Treating iron overload. N Engl J Med 368(24):2325\u20132327","journal-title":"N Engl J Med"},{"issue":"2","key":"23_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/tcrm.2007.3.2.291","volume":"3","author":"MD Cappellini","year":"2007","unstructured":"Cappellini MD (2007) Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag 3(2):291\u2013299","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"23_CR10","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","volume":"118","author":"MD Cappellini","year":"2011","unstructured":"Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A et al (2011) Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years\u2019 follow-up. Blood 118(4):884\u2013893","journal-title":"Blood"},{"issue":"14","key":"23_CR11","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.110.007641","volume":"123","author":"JP Carpenter","year":"2011","unstructured":"Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV et al (2011) On T2* magnetic resonance and cardiac iron. Circulation 123(14):1519\u20131528","journal-title":"Circulation"},{"issue":"1","key":"23_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","volume":"118","author":"A Ceci","year":"2002","unstructured":"Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V et al (2002) The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 118(1):330\u2013336","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"23_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1046\/j.1365-2362.2002.0320s1055.x","volume":"32","author":"G Cighetti","year":"2002","unstructured":"Cighetti G, Duca L, Bortone L, Sala S, Nava I, Fiorelli G et al (2002) Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Investig 32(Suppl 1):55\u201360","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"23_CR14","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","volume":"102","author":"AR Cohen","year":"2003","unstructured":"Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F (2003) Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102(5):1583\u20131587","journal-title":"Blood"},{"issue":"4","key":"23_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/ejh.12241","volume":"92","author":"AM El-Beshlawy","year":"2014","unstructured":"El-Beshlawy AM, El-Alfy MS, Sari TT, Chan LL, Tricta F (2014) Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count. Eur J Haematol 92(4):337\u2013340","journal-title":"Eur J Haematol"},{"key":"23_CR16","unstructured":"(EMA) EMA. Deferasirox (n.d.) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exjade"},{"key":"23_CR17","unstructured":"(EMA) EMa. Deferiprone (n.d.) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exjade"},{"issue":"1","key":"23_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ejh.13410","volume":"105","author":"D Farmakis","year":"2020","unstructured":"Farmakis D, Giakoumis A, Angastiniotis M, Eleftheriou A (2020) The changing epidemiology of the ageing thalassaemia populations: a position statement of the Thalassaemia international federation. Eur J Haematol 105(1):16\u201323","journal-title":"Eur J Haematol"},{"issue":"8","key":"23_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000732","volume":"6","author":"D Farmakis","year":"2022","unstructured":"Farmakis D, Porter J, Taher A, Domenica Cappellini M, Angastiniotis M, Eleftheriou A (2022) 2021 Thalassaemia International Federation Guidelines for the management of transfusion-dependent thalassemia. Hemasphere 6(8):e732","journal-title":"Hemasphere"},{"issue":"1","key":"23_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000203853","volume":"95","author":"V Gabutti","year":"1996","unstructured":"Gabutti V, Piga A (1996) Results of long-term iron-chelating therapy. Acta Haematol 95(1):26\u201336","journal-title":"Acta Haematol"},{"issue":"1","key":"23_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1532-429X-16-40","volume":"16","author":"MW Garbowski","year":"2014","unstructured":"Garbowski MW, Carpenter JP, Smith G, Roughton M, Alam MH, He T et al (2014) Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson 16(1):40","journal-title":"J Cardiovasc Magn Reson"},{"key":"23_CR22","first-page":"127","volume":"1","author":"JH Graziano","year":"1978","unstructured":"Graziano JH (1978) Iron metabolism and chelation therapy in hemosiderosis. Curr Top Hematol 1:127\u2013150","journal-title":"Curr Top Hematol"},{"issue":"1","key":"23_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj2190001","volume":"219","author":"B Halliwell","year":"1984","unstructured":"Halliwell B, Gutteridge JM (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 219(1):1\u201314","journal-title":"Biochem J"},{"issue":"2","key":"23_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.bcmd.2012.10.006","volume":"50","author":"A Lal","year":"2013","unstructured":"Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L et al (2013) Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis 50(2):99\u2013104","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"23_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","volume":"28","author":"A Maggio","year":"2002","unstructured":"Maggio A, D\u2019Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P et al (2002) Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 28(2):196\u2013208","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"23_CR26","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S2352-3026(20)30100-9","volume":"7","author":"A Maggio","year":"2020","unstructured":"Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M et al (2020) Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematol 7(6):e469\u2013ee78","journal-title":"Lancet Haematol"},{"key":"23_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2024.102859","volume":"107","author":"KM Musallam","year":"2024","unstructured":"Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A et al (2024) Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent beta-thalassemia patients who remained on the same monotherapy over 10 years. Blood Cells Mol Dis 107:102859","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"23_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood.V89.3.739","volume":"89","author":"NF Olivieri","year":"1997","unstructured":"Olivieri NF, Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89(3):739\u2013761","journal-title":"Blood"},{"issue":"14","key":"23_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1056\/NEJM199504063321404","volume":"332","author":"NF Olivieri","year":"1995","unstructured":"Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG et al (1995) Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332(14):918\u2013922","journal-title":"N Engl J Med"},{"key":"23_CR30","unstructured":"Organization Wh (n.d.) Serum ferritin concentrations for the assessment of iron status in individuals and populations: technical brief"},{"issue":"9","key":"23_CR31","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","volume":"107","author":"DJ Pennell","year":"2006","unstructured":"Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A et al (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107(9):3738\u20133744","journal-title":"Blood"},{"issue":"1","key":"23_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3324\/haematol.2010.031468","volume":"96","author":"DJ Pennell","year":"2011","unstructured":"Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y et al (2011) Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica 96(1):48\u201354","journal-title":"Haematologica"},{"issue":"7","key":"23_CR33","first-page":"873","volume":"91","author":"A Piga","year":"2006","unstructured":"Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A et al (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91(7):873\u2013880","journal-title":"Haematologica"},{"issue":"6","key":"23_CR34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2165\/00002018-199717060-00006","volume":"17","author":"JB Porter","year":"1997","unstructured":"Porter JB (1997) A risk-benefit assessment of iron-chelation therapy. Drug Saf 17(6):407\u2013421","journal-title":"Drug Saf"},{"issue":"2","key":"23_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1365-2141.2001.03195.x","volume":"115","author":"JB Porter","year":"2001","unstructured":"Porter JB (2001) Practical management of iron overload. Br J Haematol 115(2):239\u2013252","journal-title":"Br J Haematol"},{"key":"23_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.critrevonc.2015.11.017","volume":"99","author":"JB Porter","year":"2016","unstructured":"Porter JB, de Witte T, Cappellini MD, Gattermann N (2016) New insights into transfusion-related iron toxicity: implications for the oncologist. Crit Rev Oncol Hematol 99:261\u2013271","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"23_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1056\/NEJM197708252970804","volume":"297","author":"RD Propper","year":"1977","unstructured":"Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF et al (1977) Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 297(8):418\u2013423","journal-title":"N Engl J Med"},{"issue":"9","key":"23_CR38","doi-asserted-by":"publisher","first-page":"E230","DOI":"10.1002\/ajh.25860","volume":"95","author":"N Scaramellini","year":"2020","unstructured":"Scaramellini N, Consonni D, Cassinerio E, Arighi C, Marcon A, Graziadei G et al (2020) A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 mug\/L. Am J Hematol 95(9):E230\u2013E2E2","journal-title":"Am J Hematol"},{"issue":"2","key":"23_CR39","doi-asserted-by":"publisher","first-page":"xv","DOI":"10.1016\/j.hoc.2017.12.003","volume":"32","author":"AT Taher","year":"2018","unstructured":"Taher AT (2018) Thalassemia. Hematol Oncol Clin North Am 32(2):xv\u2013xvi","journal-title":"Hematol Oncol Clin North Am"},{"issue":"15","key":"23_CR40","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s40265-014-0299-0","volume":"74","author":"AT Taher","year":"2014","unstructured":"Taher AT, Cappellini MD (2014) Management of non-transfusion-dependent thalassemia: a practical guide. Drugs 74(15):1719\u20131729","journal-title":"Drugs"},{"issue":"1","key":"23_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1034\/j.1600-0609.2001.067001030.x","volume":"67","author":"A Taher","year":"2001","unstructured":"Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F (2001) Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol 67(1):30\u201334","journal-title":"Eur J Haematol"},{"issue":"6","key":"23_CR42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1600-0609.2009.01228.x","volume":"82","author":"A Taher","year":"2009","unstructured":"Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D et al (2009) Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 82(6):458\u2013465","journal-title":"Eur J Haematol"},{"issue":"10","key":"23_CR43","first-page":"1388","volume":"91","author":"MA Tanner","year":"2006","unstructured":"Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ, Thalassemia International Federation Heart TI (2006) Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 91(10):1388\u20131391","journal-title":"Haematologica"},{"issue":"6","key":"23_CR44","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1111\/bjh.16101","volume":"186","author":"A Vitrano","year":"2019","unstructured":"Vitrano A, Ruffo GB, Pepe A, D\u2019Ascola DG, Caruso V, Filosa A et al (2019) Long-term sequential deferiprone and deferasirox therapy in transfusion-dependent thalassaemia patients: a prospective clinical trial. Br J Haematol 186(6):e209\u2013ee11","journal-title":"Br J Haematol"},{"issue":"5","key":"23_CR45","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1365-2141.2011.08626.x","volume":"154","author":"E Voskaridou","year":"2011","unstructured":"Voskaridou E, Christoulas D, Terpos E (2011) Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol 154(5):654\u2013656","journal-title":"Br J Haematol"},{"issue":"4","key":"23_CR46","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/er.2015-1105","volume":"37","author":"P Wong","year":"2016","unstructured":"Wong P, Fuller PJ, Gillespie MT, Milat F (2016) Bone disease in thalassemia: a molecular and clinical overview. Endocr Rev 37(4):320\u2013346","journal-title":"Endocr Rev"},{"issue":"2","key":"23_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1046\/j.1365-2141.1998.01002.x","volume":"103","author":"B Wonke","year":"1998","unstructured":"Wonke B, Wright C, Hoffbrand AV (1998) Combined therapy with deferiprone and desferrioxamine. Br J Haematol 103(2):361\u2013364","journal-title":"Br J Haematol"},{"issue":"7","key":"23_CR48","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/MPH.0b013e3181ec0c38","volume":"32","author":"J Yacobovich","year":"2010","unstructured":"Yacobovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I et al (2010) Acquired proximal renal tubular dysfunction in beta-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol 32(7):564\u2013567","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Advances in Experimental Medicine and Biology","Iron Metabolism in Human Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-92033-2_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:01:44Z","timestamp":1776801704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-92033-2_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031920325","9783031920332"],"references-count":48,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-92033-2_23","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"3 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}